MYGN Maintained by Craig-Hallum -- Price Target Raised to $8.00
Myriad Genetics (MYGN) received a "Buy" rating from Craig-Hallum analyst John Wilkin, who significantly raised the price target from $4.00 to $8.00. While GuruFocus indicates MYGN is undervalued by 61.9% with a GF Value™ of $11.32, its low GF Score™ of 43/100 highlights concerns in growth and profitability, warranting caution for investors despite the positive analyst sentiment.
Why Is Myriad Genetics (MYGN) Stock Soaring Today
Shares of Myriad Genetics (MYGN) surged 5% after Craig-Hallum analyst John Wilkin raised the firm's price target on the stock to $8, citing an increased valuation estimate. This upward revision in the price target positively influenced investor sentiment, despite the company's recent volatile performance and a significant drop two months ago due to disappointing Q2 2026 results and a reduced full-year forecast.
Form 4 Myriad Genetics Inc For: 27 September By Investing.com
This article reports on a Form 4 filing for Myriad Genetics Inc (MYGN) on September 27. It indicates that the company's stock symbol is MYGN, which saw a +1.89% change. The content primarily consists of the title repeated and a Reuters copyright notice.
Form 4 Myriad Genetics Inc For: 27 September By Investing.com
This article reports on the filing of a Form 4 by Myriad Genetics Inc. on September 27. A Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their beneficial ownership of the company's stock. The article provides the date of the filing and mentions Myriad Genetics Inc. (MYGN) with a slight stock increase.
Myriad Genetics (MYGN) ex-CCO keeps stock-tied PSUs
Brian J. Donnelly, former Chief Commercial Officer of Myriad Genetics (MYGN), has exited his Section 16 reporting status, effective September 16, 2026. Despite his departure, he retains significant equity holdings, including 573,363 shares of common stock and performance-based restricted stock units (PSUs) representing up to 236,167 shares. The PSUs will vest based on the achievement of specific stock price milestones and certification by the Compensation and Human Capital Committee.
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Myriad Genetics has promoted Vishal Sikri to Executive Vice President - Commercial, effective September 16, 2026. Sikri, who previously served as SVP of Product, brings extensive experience in molecular diagnostics and oncology. He replaces Brian Donnelly, who will depart on September 21, 2026, and the company is reaffirming its financial guidance for the full year 2026.
Myriad Genetics (NASDAQ: MYGN) swaps commercial chief but keeps 2026 outlook
Myriad Genetics has announced a change in its commercial leadership, with Brian Donnelly stepping down as Chief Commercial Officer and Vishal Sikri being promoted to Executive Vice President, Commercial. The company reaffirmed its full-year 2026 financial guidance, initially announced on July 30, 2026. This leadership transition aims to support Myriad's focus on its cancer care continuum and profitable growth strategy.
Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset
Myriad Genetics (MYGN) has seen its modelled fair value estimate cut by nearly 46% to US$3.37 after a reset in analyst price targets and reduced FY26 guidance. This shift reflects increased caution regarding execution risk, profitability, and payer friction in certain testing volumes. Analysts have issued mixed ratings, with some maintaining neutral positions while others, like Piper Sandler, downgraded the stock due to profitability concerns.
A new commercial chief takes over at Myriad Genetics as his predecessor departs
Myriad Genetics (NASDAQ: MYGN) has appointed Vishal Sikri as Executive Vice President - Commercial, effective September 16, 2026. This promotion follows the departure of Chief Commercial Officer Brian Donnelly on September 21, 2026. The company reaffirmed its full-year 2026 financial guidance, which was initially issued on July 30, 2026.
Form 8K Myriad Genetics Inc For: 17 September By Investing.com
This article reports on the filing of a Form 8K by Myriad Genetics Inc. on September 17. The brief piece includes the stock symbol MYGN and notes a -4.83% change for the company, highlighting the financial disclosure event.
Form 8K Myriad Genetics Inc For: 17 September By Investing.com
Myriad Genetics Inc. filed a Form 8K on September 17, as reported by Investing.com. The article notes the filing and mentions Myriad Genetics' stock symbol MYGN, which saw a 7.25% increase. The content provided is primarily a placeholder for the 8K filing details, surrounded by general financial market information and advertisements.
Myriad Genetics (NASDAQ: MYGN) Confirms 2026 Financial Outlook Amid Executive Commercial Leadership Shift
Myriad Genetics has appointed Vishal Sikri as executive vice president, commercial, effective September 16, 2026, succeeding Brian Donnelly. Donnelly will remain a non-executive employee until September 21, 2026, to ensure a smooth transition. The company also reaffirmed its full-year 2026 financial guidance.
Myriad Genetics promotes Vishal Sikri to commercial chief By Investing.com
Myriad Genetics Inc. has promoted Vishal Sikri to Executive Vice President - Commercial, effective immediately. Sikri previously served as Senior Vice President of Product and replaces Brian Donnelly, who is departing the company. Myriad Genetics also reaffirmed its financial guidance for full-year 2026.
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Myriad Genetics has announced the promotion of Vishal Sikri to Executive Vice President - Commercial, effective September 16, 2026. Sikri previously served as SVP of Product and brings extensive experience in molecular diagnostics, oncology, and commercial leadership. He replaces Brian Donnelly, who will depart on September 21, 2026, and the company is reaffirming its financial guidance for the full year 2026.
Myriad Genetics And 2 Other Penny Stocks To Consider
This article examines three penny stocks—Myriad Genetics (MYGN), Octave Specialty Group (OSG), and SES AI (SES)—highlighting their financial health, challenges like unprofitability and volatility, and strategic initiatives. Despite the risks associated with penny stocks, each company shows potential through partnerships, improved debt metrics, or secured cash runways. The analysis emphasizes looking beyond traditional metrics for emerging opportunities in a fluctuating market.
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
This article reviews the Q2 earnings for therapeutics stocks, highlighting Myriad Genetics (NASDAQ:MYGN) as the weakest performer with a significant miss on revenue and EPS expectations, leading to a substantial stock drop. In contrast, Biogen (NASDAQ:BIIB) delivered the best performance, exceeding analyst expectations for revenue and EPS. The report also briefly touches on the performances of AbbVie (NYSE:ABBV), Vertex Pharmaceuticals (NASDAQ:VRTX), and United Therapeutics (NASDAQ:UTHR).
Why is Myriad Genetics stock tumbling today?
Myriad Genetics (MYGN) stock is down 7.1% today after Piper Sandler downgraded it from Overweight to Underweight, cutting the price target to $2.00 from $5.45. This downgrade follows Myriad's disappointing Q2 2026 results, which showed a significant revenue decline and reduced full-year guidance, further exacerbated by a lack of asset divestitures and a weak broader market. The stock is approaching its 52-week low amidst structural profitability concerns and a risk-off market environment.
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
Myriad Genetics, Inc. announced its management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026, at 11:00 AM EST. A live audio webcast of the presentation will be available on the investor relations section of Myriad's website. The company specializes in molecular diagnostic testing and precision medicine, focusing on tests that guide treatment decisions and improve patient care.
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation comes after Myriad Genetics reported Q2 2026 revenues that were below Wall Street consensus and subsequently cut its full-year 2026 revenue guidance, citing reimbursement pressure and collections issues. The firm is encouraging affected shareholders to inquire about the securities investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation comes after Myriad Genetics reported Q2 2026 revenue below Wall Street expectations and substantially cut its full-year 2026 revenue guidance, citing reimbursement pressure and other issues. Shareholders who purchased Myriad securities are encouraged to connect with the firm to assist with the investigation.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price after the company reported lower-than-expected Q2 2026 revenue and substantially cut its full-year guidance. The firm is encouraging shareholders who purchased Myriad securities to join the investigation, citing potential claims related to the company's prior reiteration of higher revenue guidance just months before the revision.
MYGN Maintained by Stephens & Co. -- Price Target Lowered to $3.
Stephens & Co. analyst Mason Carrico has maintained an "Equal-Weight" rating for Myriad Genetics (MYGN) but lowered its price target from $5.00 to $3.00, a 40% reduction. This reflects growing concerns about the company's financial performance, despite GuruFocus indicating the stock is 73.9% undervalued with a GF Value of $11.46 against its current price of $2.99. However, MYGN shows moderate overall performance with a GF Score of 55/100, hampered by unprofitability and a high forward P/E, suggesting caution for investors.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation comes after Myriad Genetics reported Q2 2026 revenues that were below Wall Street consensus and subsequently cut its full-year 2026 revenue guidance, citing reimbursement pressures and other issues. The firm encourages investors who purchased Myriad securities to come forward and assist in the investigation.
Marquis Who's Who Honors Ben Wheeler for Expertise in Finance and Healthcare
Ben Wheeler has been recognized by Marquis Who's Who for his significant achievements and leadership in both the finance and healthcare sectors. As the Chief Financial Officer at Myriad Genetics, Inc., he oversees crucial financial functions, investor relations, and strategic initiatives, playing a key role in the company's growth and stability. His career also highlights his expertise in acquisitions, capital markets, and people development, reinforced by his strong academic background and professional certifications.
Myriad Genetics (MYGN): Glenview Capital and Larry Robbins report exit from stake
Glenview Capital Management and Larry Robbins have reported that they no longer hold a significant ownership stake in Myriad Genetics (MYGN). An SEC filing (SCHEDULE 13G/A) indicates that as of June 30, 2026, they beneficially own 0 shares, representing 0% of the outstanding common stock. This filing confirms their exit from a previously reported ownership position in the company.
Myriad Genetics (MYGN): Vestal Point Capital discloses 6.1% stake in 13G filing
Vestal Point Capital, LP and its Chief Investment Officer Ryan Wilder have disclosed a 6.1% stake in Myriad Genetics, Inc. (MYGN) through a Schedule 13G filing. The reporting group beneficially owns 5,735,000 shares of common stock, representing 6.1% of the 94,448,210 outstanding shares as of May 1, 2026. This passive investment grants them shared voting and dispositive power over these shares, held via a Vestal Point fund and a managed account.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation comes after Myriad Genetics reported lower-than-expected Q2 2026 revenues, cut its full-year 2026 revenue guidance, and suspended its adjusted EBITDA guidance, citing reimbursement pressure and collections issues. The firm is encouraging investors who purchased Myriad securities to learn more and potentially assist in a class action.
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Kirby McInerney LLP is investigating Myriad Genetics, Inc. (NASDAQ: MYGN) following a significant stock price decline after the company reported an 11% year-over-year revenue decrease in Q2 2026 and reduced its full-year guidance. The decline was attributed to issues with payer reimbursement and revenue-cycle friction, leading to a 47% drop in Myriad's stock price. The law firm is encouraging investors who purchased Myriad Genetics securities to contact them regarding potential securities laws violations.
Myriad Genetics Faces Multiple Investor Investigations
Myriad Genetics (NASDAQ: MYGN) is facing multiple investor investigations from several law firms after reporting weaker-than-expected second-quarter results and sharply reducing its 2026 revenue outlook. The company's stock lost nearly half its value following the announcement, prompting inquiries into whether Myriad Genetics or its management made false or misleading statements to investors. The investigations are focused on the significant revenue decline, reduced guidance, and issues related to reimbursement and collection.
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN
Dimensional Fund Advisors LP significantly reduced its stake in Myriad Genetics, Inc. by 42.6% in the first quarter, selling over half a million shares. This move comes as institutional investors hold a substantial portion of the company, and analysts have become more bearish, issuing "Reduce" ratings and lowering price targets. Myriad Genetics also reported weaker-than-expected quarterly financial results, missing revenue and earnings estimates.
Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN
Assenagon Asset Management S.A. significantly reduced its stake in Myriad Genetics, Inc. by 28.7% in the second quarter, selling over 415,000 shares. This divestment follows Myriad Genetics reporting disappointing quarterly results, missing analyst expectations for both earnings and revenue, and experiencing a year-over-year revenue decline. Consequently, analyst sentiment has soured, leading to several price target cuts and a consensus "Reduce" rating for the stock.
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (NASDAQ: MYGN) securities. This investigation follows Myriad's Q2 2026 revenue report, which showed an 11% year-over-year decrease and fell short of Wall Street estimates, leading the company to cut its full-year revenue guidance and suspend adjusted EBITDA guidance. Investors are encouraged to contact the firm if they have information or purchased Myriad securities.
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky is investigating Myriad Genetics (MYGN) for potential securities law violations after the company reported lower-than-expected Q2 2026 revenue, cut its full-year revenue guidance, and suspended adjusted EBITDA guidance. The investigation focuses on whether Myriad Genetics made materially false or misleading statements regarding its financial outlook, especially since revenue guidance was reiterated just three months prior to the reduction. Investors who suffered losses on their MYGN investment are encouraged to contact Levi & Korsinsky for a free evaluation.
Myriad Genetics And 2 Other Promising Penny Stocks For Your Watchlist
This article identifies three promising "penny stocks" for investors to consider: Myriad Genetics (MYGN), Claros Mortgage Trust (CMTG), and Nextdoor Holdings (NXDR). It highlights their financial health, operational details, market capitalization, and recent performance, noting both challenges and potential for growth in a thriving market. The analysis aims to provide long-term focused insights based on fundamental data, while cautioning that it is not financial advice.
Myriad Genetics And 2 Other Promising Penny Stocks For Your Watchlist
This article identifies three promising penny stocks—Myriad Genetics (MYGN), Claros Mortgage Trust (CMTG), and Nextdoor Holdings (NXDR)—that exhibit strong financial health despite current challenges. Myriad Genetics is expanding its market reach through strategic partnerships, Claros Mortgage Trust has a solid cash runway despite unprofitability, and Nextdoor Holdings is reducing losses with robust cash flow and no debt. The article suggests these companies could offer unique opportunities for investors seeking value and growth in a thriving market.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation was triggered by Myriad's Q2 2026 revenue shortfall and a substantial cut in its full-year 2026 revenue guidance, which management attributed to reimbursement pressure, collections issues, and weaker prenatal performance. The firm is encouraging stockholders to connect and assist with the investigation, emphasizing that there is no cost to investors for their representation.
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Myriad Genetics, Inc. (NASDAQ: MYGN) for potential securities law violations. This investigation follows Myriad's Q2 2026 financial results, which showed an 11% year-over-year revenue drop, reduced full-year guidance, and suspended EBITDA guidance, causing a sharp decline in share price. SBS is encouraging affected shareholders to join the fraud investigation to discuss their rights.
Myriad Genetics (NASDAQ:MYGN) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen has downgraded Myriad Genetics (NASDAQ:MYGN) to a "Sell" rating from "Hold," citing the company's recent earnings miss and declining revenue. The stock opened significantly below its moving averages, and the analyst consensus for Myriad Genetics is now "Reduce" with an average price target of $5.38. Other analysts have also issued "Sell" or "Strong Sell" ratings, and the company has seen some insider selling recently, although there was also an insider purchase.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Myriad Genetics, Inc. (MYGN) following a significant drop in its stock price. This investigation comes after Myriad Genetics reported Q2 2026 revenues that were 11% lower year-over-year and below Wall Street expectations, leading the company to cut its full-year revenue guidance and suspend adjusted EBITDA guidance. The firm is encouraging investors who purchased Myriad securities to join the investigation.
State Street Corporation (NYSE: STT) discloses 5.3% holding in Myriad Genetics
State Street Corporation has disclosed a 5.3% beneficial ownership in Myriad Genetics, Inc. (MYGN), amounting to 4,985,060 shares. This ownership is managed through various asset management subsidiaries, with shared voting and dispositive power over the shares. The filing, a SCHEDULE 13G, indicates a passive investment, confirming no sole voting or dispositive power by State Street itself.
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating Myriad Genetics, Inc. (MYGN) after the company reported Q2 2026 revenues below Wall Street expectations and significantly cut its full-year 2026 revenue guidance. The firm encourages stockholders to contact them to learn more about the investigation into potential claims on behalf of purchasers of Myriad securities. Myriad attributed the financial shortfall to reimbursement pressures, collections issues, and lower revenue per test.
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Myriad Genetics, Inc. (MYGN) after the company reported significantly lower-than-expected Q2 2026 revenue and drastically cut its full-year 2026 guidance. This announcement followed Myriad Genetics reiterating stronger guidance just three months prior, leading to a stock price drop. The firm encourages affected investors to contact them to assist with the investigation.
MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP
Kirby McInerney LLP is investigating Myriad Genetics, Inc. (NASDAQ: MYGN) for potential securities fraud following a significant 47% stock price decline on July 31, 2026. This drop occurred after Myriad reported an 11% year-over-year revenue decrease in Q2 2026, reduced its full-year revenue guidance, and attributed the issues to lower reimbursement and "payer-generated revenue-cycle friction." The law firm is seeking investors who purchased Myriad securities to discuss their rights.
MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP
Kirby McInerney LLP has announced an investigation into Myriad Genetics, Inc. (NASDAQ: MYGN) for potential securities fraud. This follows Myriad Genetics' report of an 11% year-over-year revenue decline in Q2 2026, reduced full-year guidance, and a significant stock price drop after the announcement. The investigation will examine whether the company violated federal securities laws.
MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP
Kirby McInerney LLP is investigating Myriad Genetics, Inc. (NASDAQ: MYGN) for potential securities fraud following a significant decline in revenue and stock price. The company reported an 11% year-over-year revenue decrease in Q2 2026, reduced its full-year guidance, and saw its stock drop 47% after acknowledging issues with payer-generated revenue-cycle friction. Investors who purchased Myriad securities are encouraged to contact the firm regarding their rights.
Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
Johnson Fistel, PLLP is investigating Myriad Genetics, Inc. (MYGN) for potential federal securities law violations after the company reported an 11% year-over-year revenue decline and reduced its annual guidance. This decline was attributed to issues like lower reimbursement and unfavorable estimate changes, leading to a 47% drop in Myriad Genetics' shares on July 31, 2026. Investors who suffered losses are urged to contact Johnson Fistel for potential recovery options.
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.34, Implies 87% Upside
Myriad Genetics, Inc.'s average 12-month price target has been lowered by analysts from $5.44 to $5.34, with forecasts ranging from $3 to $10. This updated target suggests an approximate 87% potential upside based on the July 31 closing price. Despite the target cut, the consensus rating for MYGN stock remains "Hold" among 9 analysts, including 2 Buys, 5 Holds, and 2 Sells.
Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)
Levi & Korsinsky, LLP has announced an investigation into Myriad Genetics (NASDAQ: MYGN) after the company significantly cut its full-year 2026 revenue guidance and suspended adjusted EBITDA guidance. This comes just three months after reaffirming higher revenue projections, leading to investor losses. The firm is encouraging affected shareholders to submit their loss information for a potential securities fraud claim.
Why Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook On Prenatal Weakness
Myriad Genetics (MYGN) shares dropped 49% after the company cut its 2026 revenue outlook to US$770-790 million, down from US$190.7 million, primarily due to weaker Prenatal Health test volumes. Despite a narrowed net loss, the reduced forecast highlights ongoing pressure on test volumes and pricing, making the stabilization of Prenatal Health a key focus for investors. The company is attempting to diversify through oncology partnerships, but immediate concerns remain about prenatal test demand and reimbursement.
Why Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook On Prenatal Weakness
Myriad Genetics (MYGN) shares fell 49.0% after the company cut its full-year 2026 revenue outlook due to weaker Prenatal Health test volumes and more cautious assumptions for revenue per test. While the company's net loss narrowed, the immediate pressure on its Prenatal Health segment raises concerns for investors. The article highlights Myriad's strategy to diversify into oncology to offset these pressures and mentions that analysts were already cautious about the company's growth prospects.
